Current Concepts in Antifungal Pharmacology

被引：278

作者：

Lewis, Russell E. ^{[1
,2
]}

机构：

[1] Univ Houston, Coll Pharm, Unit 424, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

MAYO CLINIC PROCEEDINGS | 2011年 / 86卷 / 08期

关键词：

INVASIVE PULMONARY ASPERGILLOSIS; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; LIPOSOMAL AMPHOTERICIN-B; MURINE MODEL; FUNGAL-INFECTIONS; DRUG-INTERACTIONS; AZOLE ANTIFUNGALS; IN-VITRO; POSACONAZOLE;

D O I：

10.4065/mcp.2011.0247

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles) in the past decade has transformed the management of invasive mycoses to the point that drug toxicity is no longer the major limiting factor in treatment. Yet, many of these newer antifungal agents have important limitations in their spectrum of activity, pharmacokinetics, and unique predisposition for pharmacokinetic drug-drug interactions and unusual toxicities associated with long-term use. This article reviews key pharmacological aspects of systemic antifungal agents as well as evolving strategies, such as pharmacokinetic-pharmacodynamic optimization and therapeutic drug monitoring, to improve the safety and efficacy of systemic antifungal therapy.

引用

页码：805 / 817

页数：13

共 109 条

[1] Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome [J].

AbuTarif, M. A. ;

Krishna, G. ;

Statkevich, P. .

CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (02) :397-405

[2] Congestive heart failure associated with itraconazole [J].

Ahmad, SR ;

Singer, SJ ;

Leissa, BG .

LANCET, 2001, 357 (9270) :1766-1767

[3] Systemic antifungal agents - Drug interactions of clinical significance [J].

Albengres, E ;

Le Louet, H ;

Tillement, JP .

DRUG SAFETY, 1998, 18 (02) :83-97

[4] Omeprazole Significantly Reduces Posaconazole Serum Trough Level [J].

Alffenaar, Jan-Willem C. ;

van Assen, Sander ;

van der Werf, Tjip S. ;

Kosterink, Jos G. W. ;

Uges, Donald R. A. .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) :839-839

[5] Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models [J].

Andes, D ;

Safdar, N ;

Marchillo, K ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :674-684

[6] Clinical pharmacodynamics of antifungals [J].

Andes, D .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :635-+

[7] Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].

Andes, D ;

van Ogtrop, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120

[8] In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].

Andes, D ;

van Ogtrop, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942

[9] In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species [J].

Andes, D. ;

Diekema, D. J. ;

Pfaller, M. A. ;

Bohrmuller, J. ;

Marchillo, K. ;

Lepak, A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2497-2506

[10] Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].

Andes, D ;

Marchillo, K ;

Conklin, R ;

Krishna, G ;

Ezzet, F ;

Cacciapuoti, A ;

Loebenberg, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142

← 1 2 3 4 5 6 7 8 9 10 →